Sep 2026· New England Journal of Medicine· Vol 395, pp. 1374 - 1386· 4 citations· ⚡ 1 influential· 30 references
Medicine
TL;DR
In NHS-Galleri, the authors did not observe a reduction in stage III/IV cancers across 12 prespecified cancers after 3 screening rounds when MCED testing was added to standard-of-care.
Abstract
Background NHS-Galleri, a randomized controlled trial, evaluates the clinical utility of a blood-based multi-cancer early detection (MCED) test added to usual care among individuals aged 50-77 years in England. Methods Peripheral blood was collected at up to 3 annual visits. Following baseline blood collection, participants were randomized 1:1 to intervention (blood tested) or control (blood stored) arms. Participants and study personnel were initially blinded. Reductions of stage III/IV (primary endpoint) and IV (key secondary) cancers of 12 prespecified types in intervention vs control were measured ~3 years after the last participant’s randomization. Results Overall, 71,122 and 71,128 participants were randomized to intervention and control arm, respectively. The primary endpoint was not met (incidence rate ratio [IRR; intervention vs control]:1.03 [0.92-1.14], p=0.63). For secondary endpoints, the IRR for stage IV cancer after 3 screening rounds was 0.86 (0.74-1.00). <1% of participants experienced related adverse events, none were serious. Conclusions In NHS-Galleri, we did not observe a reduction in stage III/IV cancers across 12 prespecified cancers after 3 screening rounds when MCED testing was added to standard-of-care. Further follow-up is planned to assess how findings for stage III/IV cancers and the difference in stage IV cancers evolve over time. (Funded by GRAIL, Inc.; ClinicalTrials.gov #NCT05611632)
The NHS-Galleri trial was a randomized controlled trial evaluating a multi-cancer early detection (MCED) test added to usual care. We reported elsewhere that the primary endpoint of a reduction in the incidence of stage III/IV cancer diagnoses in the intervention arm versus control arm was not met. Here we report presp...
Richard D. Neal, S. Dolly, Peter Johnson et al.· Nature Medicine· 5 citations· ⚡1
Early cancer detection improves survival; however, most cancer types do not have guideline-recommended screening. We previously reported the first PATHFINDER study that established feasibility of cancer screening with a blood-based multi-cancer early detection (MCED) test that predicts cancer signal origin (CSO) to gui...
N. Nabavizadeh, C. McDonnell, D. Kurbegov et al.· Nature Medicine· 6 citations· ⚡1
638
Background:
Early-onset colorectal cancer (EOCRC) incidence is rising but data on survival and recurrence compared with late-onset CRC remain limited, contributing to under- and over-use of surveillance. We evaluated receipt of surveillance in a diverse population-based sample of EOCRC survivors and identif...
Christine M. Veenstra, E. Stoffel, S. Hawley et al.· JCO Oncology Practice· 0 citations
Abstract Introduction Lung cancer (LC) is the leading cause of cancer-related mortality, largely due to late-stage diagnosis. Thus, early detection improves outcomes and survival. Low-dose computed tomography (LDCT) enables early detection in high-risk populations, although many LC cases fall outside current screening...
J. Orcajo, J. Idoyaga-Uribarrena, A. Vélez-Del-Burgo et al.· European Journal of Public H...· 0 citations
Non-cancer mortality remains elevated among cervical cancer survivors, including beyond the 5-year landmark, and treatment-group contrasts are strongly affected by disease stage, treatment-selection mechanisms, and unmeasured clinical factors; they should be interpreted as hypothesis-generating rather than causal.
Shan-Shan Wang, Jing-Xin Ding, Xiao-Qin Chen et al.· Journal of Gynecologic Oncol...· 0 citations
BACKGROUND
Optimizing surveillance for the growing population of breast cancer survivors remains a challenge. Although screening guidelines for initial breast cancer are well established, current surveillance guidelines recommending routine provider examinations rely heavily on expert consensus rather than real-world d...
A. Duffens, Cecile A. Laurent, I. Ergas et al.· The Journal of the National...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.